Posts by Simak
Super insight into regulation of CDK activities @vcushing.bsky.social, @bjgreber.bsky.social
Our paper showing that acquired resistance to CDK inhibitors can result from simple mutations in the CDK gene is now out - thanks to Chun-Fui Lai, @vcushing.bsky.social @bjgreber.bsky.social with support from @prostatecanceruk.bsky.social @imperialsandc.bsky.social www.embopress.org/doi/full/10....
The contact of Reform UK's Russian puppet Nathan Gill is linked to efforts to destabilise the US and Ukraine. Why, even now, is no one asking questions?
More than just a bad apple: why we must look closer at the Nathan Gill scandal
New evidence connects the Ukrainian politician who paid bribes to Gill - Reform UK’s former leader in Wales - to a campaign to destabilise the US election
@carolecadwalla.bsky.social reports
Scientific Paper Published in The EMBO Journal, titled: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. Written by Lai et al.
Can specific gene mutations drive CDK7 inhibitor resistance in #ProstateCancer?
A brilliant team led by @simak.bsky.social @imperialcollegeldn.bsky.social share exciting new findings in @embojournal.org.
Grab a ☕ and read: doi.org/10.1038/s443...
We show a single amino acid change in CDK7 causes acquired resistance to CDK7i in cancer cells. There are implications for patient selection,resistance monitoring and switching treatments. thanks to @vcushing.bsky.social @bjgreber.bsky.social @prostatecanceruk.bsky.social
doi.org/10.1038/s443...
This will be a great meeting - and in the sunniest part of the UK!
www.nature.com/articles/s41...
A fantastic paper on the dynamics of the estrogen receptor N-terminal domain. A big win for the field and the Yang lab should be commended on their seminal study!
Our publication in Cancer Research (DOI: 10.1158/0008-5472.CAN-24-0013) reveals a route to hormone therapy resistance in #ER-positive breast cancer patients. We show that induction of #VGLL1 drives gene expression programmes that confer resistance to ER degraders.
As a co-chair of the Training and Career Development Core Committee, I’m proud to highlight the Endocrine Society’s commitment to fostering the next generation of leaders in endocrinology through these transformative programs. Having seen firsthand their impact, I can attest to their power in equipping trainees with the skills, connections, and recognition they need to excel and lead in the field. Applications for these programs close soon on Wednesday, January 15, and we want to ensure your trainees don’t miss this opportunity. By encouraging them to apply, you can help them access workshops, mentorship, networking, and awards designed to elevate their careers. The Early Investigator Awards (EIA) celebrate exceptional research in endocrinology. Awardees receive a $1,000 prize, complimentary ENDO 2025 registration, a one-year Society membership, and public recognition of their accomplishments. The Early Career Forum Travel Award (ECF) provides access to an exclusive professional development workshop at the ENDO annual meeting. Travel awardees receive complimentary registrations for ENDO 2025 and the ECF workshop, plus a $400 travel grant. The Research Experiences for Graduate and Medical Students (REGMS) program supports promising 1st to 3rd year medical or graduate students through hands-on research experience and mentorship from Endocrine Society members. Participants receive a $2,500 honorarium, an 8-week webinar series, career development opportunities, and the opportunity to present research at ENDO 2026 with a $1,500 travel grant. Your recommendation and encouragement could make all the difference for a trainee considering these opportunities. Please share this information with your students and fellows and help us support the next generation of leaders in endocrinology. Thank you for your partnership in fostering the careers of tomorrow’s endocrine professionals.
Applications for Endocrine Society's awards programs are open until 1/15, including key early career programs, e.g. Early Career Forum & REGMS research fellowship.
These programs are a gateway to grow careers in endocrinology and in ES as a professional home. Apply today!
www.endocrine.org/awards
Our work flags new therapeutic opportunities for patients who progress on/after hormone therapies, including VGLL1/TEAD inhibitors & drugs targeting EGFR
Thanks to a super collaboration with @magnanilab.bsky.social, funding from @cancerresearchuk.org and support from @imperialsandc.bsky.social
Our publication in Cancer Research (DOI: 10.1158/0008-5472.CAN-24-0013) reveals a route to hormone therapy resistance in #ER-positive breast cancer patients. We show that induction of #VGLL1 drives gene expression programmes that confer resistance to ER degraders.
Super lineup for this conference.
Almost 1 month left to submit your abstract for the #Epigenetics2025 conference, organized by @gensocuk.bsky.social
We’ve put together a fantastic scientific program, and Northern Ireland is a wonderful destination to explore.
Yet….. It seems from the data that there is a tendency for better efficacy in CDK4/6i-first. But the p-value is 0.1… what if the n were bigger?
The tyranny of the p-value? #oncoSky #oncosky🧪
Gene regulation involves thousands of proteins that bind DNA, yet comprehensively mapping these is challenging. Our paper in Nature Genetics describes ChIP-DIP, a method for genome-wide mapping of hundreds of DNA-protein interactions in a single experiment.
www.nature.com/articles/s41...
📢 Looking for a #postdoc position in the intersection of #cancer, #chromatin and #epigenetics??? Still a few days left to apply to our lab in wonderful Denmark as part of the new translational cancer hub initiative🇩🇰🧪👇🏻
In other news millions of people in the UK are living in poverty, destitution & using food banks
From these data, we derived the mechanism of CDK7-selectivity of the clinical compound and formulated a hypothesis for a secondary mechanism of selectivity in this compound class. We tested this hypothesis successfully by analysis of the compound CT7030.
Ok first post on Bluesky and it’s a science one… New paper out from the lab! APOBEC genes protect us from viral infection but go rogue in cancer. Here we shed new light on how these important genes are regulated, offering clues as to what goes wrong in cancer.
www.embopress.org/doi/full/10....
It’s so important we support @bylinetimes.bsky.social. It’s the newspaper we’ve all been waiting for. Truly independent journalism at its very best
subscribe.bylinetimes.com
A number of artists and creators have made their home on Bluesky, and we hear their concerns with other platforms training on their data. We do not use any of your content to train generative AI, and have no intention of doing so.
This was missed due to major live events happening around the same time, but we have released some of our high-resolution (2 Å) and rapid screening #cryoEM maps & models of the human CAK bound to small molecules. Paper still under review - more to follow.
www.ebi.ac.uk/emdb/search/...